SynthesisThe International journal of artificial organs2023
The ProtekDuo in ECMO configuration for ARDS secondary to COVID-19: A systematic review.
Synthesis in The International journal of artificial organs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- Synchronized Cardiac Support with Veno-Pulmonary Extracorporeal Membrane Oxygenation in a Simulation Mannequin.Annals of biomedical engineering · 2026Article
- Treatment protocol for pneumonia with acute kidney injury: effects of ulinastatin combined with CRRT on inflammatory factors and renal function in patients.Frontiers in medicine · 2026Article
- Modelling and Simulation of the Interactions Between the Cardiovascular System and the Combined Use of VA ECMO and IABP: Comparison Between Peripheral and Central Configurations.Bioengineering (Basel, Switzerland) · 2025Article
- The ProtekDuo Cannula for Venopulmonary ECMO as Bridge to Lung Transplantation: A Single Center Case Series.Annals of cardiac anaesthesia · 2025Article
- The application of mechanical circulatory support in special conditions.European heart journal supplements : journal of the European Society of Cardiology · 2025Article
- Navigating Heart-Lung Interactions in Mechanical Ventilation: Pathophysiology, Diagnosis, and Advanced Management Strategies in Acute Respiratory Distress Syndrome and Beyond.Journal of clinical medicine · 2024Article
- Outcome of Veno-Pulmonary Extracorporeal Life Support in Lung Transplantation Using ProtekDuo Cannula: A Systematic Review and Description of Configurations.Journal of clinical medicine · 2024Review
- The ProtekDuo Cannula: A Comprehensive Review of Efficacy and Clinical Applications in Right Ventricular Failure.Journal of clinical medicine · 2024Review
- Transesophageal Echocardiography-Guided ProtekDuo Percutaneous Temporary Right Ventricular Assist Device Cannulation Technique.Annals of cardiac anaesthesia · 2024Article
- Refractory cor pulmonale under extracorporeal membrane oxygenation for acute respiratory distress syndrome: the role of conversion to veno-pulmonary arterial assist-a case series.Frontiers in medicine · 2024Article
- Outcomes of patients with COVID-19 supported by venovenous extracorporeal membrane oxygenation for greater than 90 days.JTCVS open · 2023Article
- The protekduo cannula for acute right ventricular support in thyrotoxicosis.Annals of cardiac anaesthesiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAssessment of the results of the ProtekDuo cannula applied for dedicated right ventricular support with oxygenator in ARDS secondary to COVID-19.
methodsSystematic literature search in NHS library, Medline (Pubmed) and EMBASE using appropriate keywords as well as PICOS and PRISMA approach.
resultsOut of 285 publications found, 5 publications met the search criteria and were included in this review. A total of 194 patients with ARDS secondary to COVID-19 underwent ProtekDuo placement to establish a combination of respiratory [veno-venous extracorporeal membrane oxygenation (V-V ECMO)] and right ventricular support. Patients treated using the ProtekDuo cannula had survival rates between 59% and 89% throughout the five studies, and a significant survival benefit when compared to an invasive ventilation group or compared to dual site V-V ECMO or other double lumen ECMO cannulas. One study focused on extubation and discontinuation of ventilator support, which could be achieved in 100% of ProtekDuo patients. An association for reduced incidence of acute kidney injury (AKI) and use of continuous renal replacement therapy (CRRT) could be shown when the ProtekDuo was used.
conclusionOnly limited literature is available for the ProtekDuo in V-P ECMO configuration in the setting of COVID-19 ARDS and should be interpreted with caution. Data on the ProtekDuo is suggestive for lower rates of mortality, AKI and CRRT as compared to other respiratory support modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.